EDMONTON, May 1 /PRNewswire/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer, Inc. The protein will be manufactured at QSV's Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.
Graeme Macaloney PhD, PEng, Founder, President & CEO of QSV said: "We are extremely pleased and honoured that Pfizer has chosen QSV Biologics from a strong field of contending CMOs as their manufacturing partner for this project. The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV's continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer."
"Pfizer is pleased to engage QSV for the clinical manufacturing of a complex biotechnology product," said Rick Rutter, Ph.D., Vice President of Global Biologics in the Pharmaceutical Sciences division of Pfizer Global Research and Development. "Speed to clinic is of great importance for early development candidates and QSV has a record of delivering quality product on-time and on-budget. QSV will play a supporting role in realizing Pfizer's vision of becoming a top tier biotherapeutic company."
QSV Biologics, Ltd. (http://www.qsvbiologics.com), is an international cGMP
biologics contract manufacturer (CMO) providing microbial fermentation &
cell culture, and purification services. QSV's facility has a 12 yr track
record including an Establishment License for manufacturing clinical trial
and commercial biologics. QSV was the sole recipient of the prestigious
international Frost & Sullivan "Cu
|SOURCE QSV Biologics, Ltd.|
Copyright©2008 PR Newswire.
All rights reserved